دورية أكاديمية
أعرض في EDS

Chronotherapy: Intuitive, Sound, Founded…But Not Broadly Applied.

التفاصيل البيبلوغرافية
العنوان: Chronotherapy: Intuitive, Sound, Founded…But Not Broadly Applied.
المؤلفون: Selfridge JM; Virginia Tech Carilion School of Medicine and Research Institute, 2 Riverside Circle, Roanoke, VA, 24016, USA.; Integrated Cellular Responses Laboratory, Department of Biological Sciences, Biocomplexity Institute, 1015 Life Science Circle, Virginia Tech, Blacksburg, VA, 24061, USA., Gotoh T; Integrated Cellular Responses Laboratory, Department of Biological Sciences, Biocomplexity Institute, 1015 Life Science Circle, Virginia Tech, Blacksburg, VA, 24061, USA., Schiffhauer S; Integrated Cellular Responses Laboratory, Department of Biological Sciences, Biocomplexity Institute, 1015 Life Science Circle, Virginia Tech, Blacksburg, VA, 24061, USA., Liu J; Integrated Cellular Responses Laboratory, Department of Biological Sciences, Biocomplexity Institute, 1015 Life Science Circle, Virginia Tech, Blacksburg, VA, 24061, USA., Stauffer PE; Integrated Cellular Responses Laboratory, Department of Biological Sciences, Biocomplexity Institute, 1015 Life Science Circle, Virginia Tech, Blacksburg, VA, 24061, USA., Li A; Virginia Tech Carilion School of Medicine and Research Institute, 2 Riverside Circle, Roanoke, VA, 24016, USA.; Integrated Cellular Responses Laboratory, Department of Biological Sciences, Biocomplexity Institute, 1015 Life Science Circle, Virginia Tech, Blacksburg, VA, 24061, USA., Capelluto DG; Protein Signaling Domains Laboratory, Department of Biological Sciences, Biocomplexity Institute, 1015 Life Science Circle, Virginia Tech, Blacksburg, VA, 24061, USA.; Center for Soft Matter and Biological Physics, Virginia Tech, Blacksburg, VA, 24061, USA., Finkielstein CV; Virginia Tech Carilion School of Medicine and Research Institute, 2 Riverside Circle, Roanoke, VA, 24016, USA. finkielc@vt.edu.; Integrated Cellular Responses Laboratory, Department of Biological Sciences, Biocomplexity Institute, 1015 Life Science Circle, Virginia Tech, Blacksburg, VA, 24061, USA. finkielc@vt.edu.
المصدر: Drugs [Drugs] 2016 Oct; Vol. 76 (16), pp. 1507-1521.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 7600076 Publication Model: Print Cited Medium: Internet ISSN: 1179-1950 (Electronic) Linking ISSN: 00126667 NLM ISO Abbreviation: Drugs Subsets: MEDLINE
أسماء مطبوعة: Publication: Auckland : Adis, Springer International
Original Publication: New York, ADIS Press [etc.]
مواضيع طبية MeSH: Circadian Rhythm/*physiology , Inactivation, Metabolic/*physiology, Chronotherapy ; Humans
مستخلص: Circadian rhythms are a collection of endogenously driven biochemical, physiological, and behavioral processes that oscillate in a 24-h cycle and can be entrained by external cues. Circadian clock molecules are responsible for the expression of regulatory components that modulate, among others, the cell's metabolism and energy consumption. In clinical practice, the regulation of clock mechanisms is relevant to biotransformation of therapeutics. Accordingly, xenobiotic metabolism and detoxification, the two processes that directly influence drug effectiveness and toxicity, are direct manifestations of the daily oscillations of the cellular and biochemical processes taking place within the gastrointestinal, hepatic/biliary, and renal/urologic systems. Consequently, the impact of circadian timing should be factored in when developing therapeutic regimens aimed at achieving maximum efficacy, minimum toxicity, and decreased adverse effects in a patient. However, and despite a strong mechanistic foundation, only 0.16 % of ongoing clinical trials worldwide exploit the concept of 'time-of-day' administration to develop safer and more effective therapies. In this article, we (1) emphasize points of control at which circadian biology intersects critical processes governing treatment interventions; (2) explore the extent to which chronotherapeutics are incorporated into clinical trials; (3) recognize roadblocks; and (4) recommend approaches to precipitate the integration of chronobiological concepts into clinical practice.
Competing Interests: The authors have declared that no conflicting interest exists. Funding This work was supported by grants from the National Science Foundation (MCB-1517298) and the Fralin Life Science Institute to CVF.
References: Chronobiol Int. 2006;23(5):1035-46. (PMID: 17050216)
PLoS Biol. 2012;10(11):e1001442. (PMID: 23209382)
Cell Mol Biol (Noisy-le-grand). 2005 Sep 05;51(3):307-20. (PMID: 16191399)
Science. 2010 Dec 3;330(6009):1349-54. (PMID: 21127246)
Nat Med. 2010 Jan;16(1):67-74. (PMID: 20023637)
Chronobiol Int. 1991;8(6):485-94. (PMID: 1799930)
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16523-8. (PMID: 19805330)
Chronobiol Int. 2006;23 (1-2):129-34. (PMID: 16687286)
Science. 2009 May 1;324(5927):651-4. (PMID: 19299583)
Curr Biol. 2002 Apr 2;12(7):540-50. (PMID: 11937022)
Neuropharmacology. 2012 Jan;62(1):101-14. (PMID: 21871466)
Cell. 2008 Jul 25;134(2):329-40. (PMID: 18662547)
Mol Cell Biol. 2004 Jan;24(2):584-94. (PMID: 14701732)
Chronobiol Int. 2005;22(4):655-65. (PMID: 16147897)
Hypertension. 1999 Jan;33(1 Pt 2):248-55. (PMID: 9931112)
Nat Rev Mol Cell Biol. 2007 Feb;8(2):139-48. (PMID: 17245414)
Br J Clin Pharmacol. 1991 Nov;32(5):627-9. (PMID: 1954078)
Int J Cancer. 2012 Dec 1;131(11):2547-52. (PMID: 22473669)
Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):175-92. (PMID: 18248311)
Mol Cell. 2012 Jul 27;47(2):158-67. (PMID: 22841001)
Curr Biol. 2016 May 23;26(10):R432-43. (PMID: 27218855)
Cell. 1999 Jul 23;98(2):193-205. (PMID: 10428031)
Clin Exp Pharmacol Physiol. 2009 Oct;36(10):1041-8. (PMID: 19566817)
Genes Dev. 2012 Dec 15;26(24):2724-36. (PMID: 23249735)
J Biochem. 2008 Nov;144(5):609-18. (PMID: 18782782)
Annu Rev Pharmacol Toxicol. 1992;32:51-66. (PMID: 1605576)
J Clin Invest. 2011 Jun;121(6):2133-41. (PMID: 21633182)
Cell. 2006 May 5;125(3):497-508. (PMID: 16678094)
Science. 1998 Jun 5;280(5369):1564-9. (PMID: 9616112)
Nature. 2000 Feb 17;403(6771):795-800. (PMID: 10693811)
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16219-24. (PMID: 25349387)
Int J Clin Pharm. 2013 Jun;35(3):344-58. (PMID: 23329340)
Science. 2012 Oct 19;338(6105):349-54. (PMID: 22936566)
Mol Biol Cell. 2014 Oct 1;25(19):3081-93. (PMID: 25103245)
Science. 2005 May 13;308(5724):1043-5. (PMID: 15845877)
Annu Rev Biochem. 2002;71:307-31. (PMID: 12045099)
J Circadian Rhythms. 2015 Nov 05;13:7. (PMID: 27103933)
Elife. 2012 Nov 13;1:e00011. (PMID: 23150795)
Science. 2009 May 1;324(5927):654-7. (PMID: 19286518)
BMC Cancer. 2016 Apr 21;16:285. (PMID: 27102330)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
J Biol Rhythms. 2015 Apr;30(2):155-60. (PMID: 25724980)
Fundam Clin Pharmacol. 2005 Feb;19(1):117-25. (PMID: 15660968)
Mol Cell Biol. 2010 Dec;30(24):5636-48. (PMID: 20937769)
Science. 2006 Feb 17;311(5763):1002-5. (PMID: 16484495)
Annu Rev Pharmacol Toxicol. 2010;50:377-421. (PMID: 20055686)
Cell. 2001 Dec 28;107(7):855-67. (PMID: 11779462)
Cell Metab. 2011 Feb 2;13(2):125-37. (PMID: 21284980)
Cell. 2007 Jun 1;129(5):1011-23. (PMID: 17462724)
Nat Rev Neurosci. 2013 Jan;14 (1):69-75. (PMID: 23187814)
J Pharmacol Sci. 2008 Sep;108(1):144-8. (PMID: 18787306)
Science. 2011 Mar 11;331(6022):1315-9. (PMID: 21393543)
JAMA. 2013 Jun 26;309(24):2559-60. (PMID: 23712449)
Physiol Rev. 2010 Jul;90(3):1063-102. (PMID: 20664079)
Ann N Y Acad Sci. 1991;618:166-81. (PMID: 2006786)
PLoS Biol. 2011 Feb;9(2):e1000595. (PMID: 21364973)
Nat Rev Cancer. 2009 Dec;9(12):886-96. (PMID: 19935677)
J Lipid Res. 2009 Sep;50(9):1800-13. (PMID: 19387090)
Cell. 2002 May 3;109(3):307-20. (PMID: 12015981)
Am J Physiol. 1968 Nov;215(5):1096-101. (PMID: 4176820)
Annu Rev Pharmacol Toxicol. 2007;47:593-628. (PMID: 17209800)
Adv Genet. 2011;74:175-230. (PMID: 21924978)
Pharmacogenomics. 2007 Mar;8(3):257-65. (PMID: 17324113)
Handb Exp Pharmacol. 2013;(217):243-60. (PMID: 23604482)
Gastroenterology. 1987 Sep;93(3):515-8. (PMID: 3609660)
Annu Rev Physiol. 2010;72:517-49. (PMID: 20148687)
Clin Pharmacokinet. 1994 Jun;26(6):419-27. (PMID: 7915223)
Methods Find Exp Clin Pharmacol. 1994 Jan-Feb;16(1):57-75. (PMID: 8164474)
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5474-9. (PMID: 9576906)
Gastroenterology. 1986 Oct;91(4):926-30. (PMID: 3743969)
Circ Res. 2011 Apr 15;108(8):980-4. (PMID: 21474818)
Annu Rev Pharmacol Toxicol. 2010;50:187-214. (PMID: 20055702)
Nature. 2002 May 2;417(6884):78-83. (PMID: 11967526)
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3342-7. (PMID: 17360649)
Sleep Med Rev. 2012 Apr;16(2):151-66. (PMID: 21641838)
Lancet. 2007 Mar 31;369(9567):1117-29. (PMID: 17398311)
Science. 2007 May 11;316(5826):900-4. (PMID: 17463251)
Clin Sci (Lond). 1989 Jul;77(1):105-11. (PMID: 2667855)
Mol Cell Biol. 2005 Apr;25(7):2795-807. (PMID: 15767683)
Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17. (PMID: 20542067)
Circ Res. 2010 Jan 8;106(1):68-78. (PMID: 20056947)
Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):979-1001. (PMID: 20600409)
Cell. 2007 May 4;129(3):461-4. (PMID: 17482541)
Mol Biol Cell. 2015 Jan 15;26(2):359-72. (PMID: 25411341)
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3407-12. (PMID: 15689397)
Cancer Causes Control. 2015 Jan;26(1):25-33. (PMID: 25388799)
JAMA. 2015 Jun 2;313(21):2119-20. (PMID: 25928209)
J Cell Sci. 2010 Nov 15;123(Pt 22):3837-48. (PMID: 21048160)
Annu Rev Pharmacol Toxicol. 2014;54:339-61. (PMID: 24160700)
J Intern Med. 2015 May;277(5):513-27. (PMID: 25599827)
Trends Mol Med. 2016 May;22(5):430-45. (PMID: 27066876)
Cell. 2002 Jul 26;110(2):251-60. (PMID: 12150932)
J Res Pharm Pract. 2012 Jul;1(1):3-9. (PMID: 24991580)
Transplant Proc. 2003 Jun;35(4):1449-51. (PMID: 12826188)
Front Mol Neurosci. 2012 Mar 26;5:37. (PMID: 22470318)
تواريخ الأحداث: Date Created: 20161005 Date Completed: 20170323 Latest Revision: 20220409
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC5082589
DOI: 10.1007/s40265-016-0646-4
PMID: 27699644
قاعدة البيانات: MEDLINE
الوصف
تدمد:1179-1950
DOI:10.1007/s40265-016-0646-4